These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 18424820)

  • 1. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
    de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
    Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.
    Kawata T; Imanishi Y; Kobayashi K; Kenko T; Wada M; Ishimura E; Miki T; Nagano N; Inaba M; Arnold A; Nishizawa Y
    Eur J Endocrinol; 2005 Oct; 153(4):587-94. PubMed ID: 16189180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism.
    Malberti F; Farina M; Imbasciati E
    Nephrol Dial Transplant; 1999 Oct; 14(10):2398-406. PubMed ID: 10528664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
    Nagano N
    Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl.
    Nemeth EF; Heaton WH; Miller M; Fox J; Balandrin MF; Van Wagenen BC; Colloton M; Karbon W; Scherrer J; Shatzen E; Rishton G; Scully S; Qi M; Harris R; Lacey D; Martin D
    J Pharmacol Exp Ther; 2004 Feb; 308(2):627-35. PubMed ID: 14593085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
    Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
    Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
    Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet reduces the set point of the PTH-calcium curve.
    Valle C; Rodriguez M; Santamaría R; Almaden Y; Rodriguez ME; Cañadillas S; Martin-Malo A; Aljama P
    J Am Soc Nephrol; 2008 Dec; 19(12):2430-6. PubMed ID: 18632847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism.
    Schwarz A; Merkel S; Leitolf H; Haller H
    Transplantation; 2011 Mar; 91(5):560-5. PubMed ID: 21192318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of reversed whole PTH/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient.
    Komaba H; Shin J; Fukagawa M
    Nephrol Dial Transplant; 2010 Feb; 25(2):638-41. PubMed ID: 19892751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve.
    Bas S; Aguilera-Tejero E; Bas A; Estepa JC; Lopez I; Madueño JA; Rodriguez M
    J Endocrinol; 2005 Jan; 184(1):241-7. PubMed ID: 15642800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M; Pontoriero G; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Zani VJ; Carter D; Messa P
    Nephron Clin Pract; 2009; 112(1):c41-50. PubMed ID: 19365139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid expression of calcium-sensing receptor protein and in vivo parathyroid hormone-Ca(2+) set-point in patients with primary hyperparathyroidism.
    Cetani F; Picone A; Cerrai P; Vignali E; Borsari S; Pardi E; Viacava P; Naccarato AG; Miccoli P; Kifor O; Brown EM; Pinchera A; Marcocci C
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4789-94. PubMed ID: 11134144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet for the treatment of primary hyperparathyroidism.
    Sajid-Crockett S; Singer FR; Hershman JM
    Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.